



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



LETTER TO THE EDITOR

Predictors of reduced 6-minute walk distance after COVID-19: a cohort study in Mexico



Clinical sequelae after COVID-19 have been well described, including abnormalities in pulmonary function tests, chest imaging, and patient-reported outcome measures.^{1,2} However, functional outcomes after COVID-19 are not well understood. We sought to identify the presence and underlying mechanisms of functional impairments after COVID-19. We hypothesized that patients with more severe COVID-19 would have a lower 6-minute walk distance (6MWD) at follow-up and that exertional dyspnea, fatigue, and hypoxemia would independently predict a lower 6MWD.

This was a consecutively-enrolled prospective cohort study. Patients who were seen in a hospital in Yucatan, Mexico with SARS-CoV-2 confirmed by real-time polymerase chain reaction were referred to a COVID-19 clinic for follow-up. Patients who were able to complete surveys, pulmonary function tests (PFTs), and 6-minute walk tests (6MWTs) were included. There were no exclusion criteria. PFTs and 6MWTs were conducted according to international guidelines.^{3–5} Patients did not receive formal physical rehabilitation during their recovery. This study received institutional ethics approval.

COVID-19 severity was categorized as mild (no hypoxemia), moderate (hypoxemia without mechanical ventilation), or severe (hypoxemia with mechanical ventilation). The association between COVID-19 severity and 6MWD was determined using multivariable linear regression, and underlying mechanisms for reduced 6MWD were then explored. Unadjusted and adjusted linear regression models were used to determine the association between potential predictor variables (Borg dyspnea, Borg fatigue, and end-exercise SpO₂) and 6MWD, first in separate models and then in a final model with both Borg dyspnea and end-exercise SpO₂ as co-primary endpoints to explore the independent relationship of these two predictors with 6MWD. All models were adjusted for age, sex, smoking, body mass index (BMI), and time from symptom onset. Statistical analyses were performed using R version 3.6.3 (R Foundation).

A total of 295 patients were referred to the COVID-19 clinic between May and August 2020, of whom 225 were enrolled (65 patients declined and 5 were lost to follow-up). The overall cohort had 62% males and 19% ever-smokers, with a mean age of 47 ± 13 years and BMI of 32 ± 7 kg/m² (Table 1). There were 63 patients with mild, 144 with moderate, and 18 with severe COVID-19. The median follow-up time was 61 days (interquartile range [IQR] 50–75), with fatigue on effort (68%) and dyspnea (39%) being the most common symptoms.

Patients with moderate or severe COVID-19 had a lower 6MWD compared to patients with mild disease (–51 m [95%CI –85, –17], p=0.004 or –68 m [95%CI –134, –3], p=0.04 respectively), with no difference between moderate and severe groups (p=0.55). 6MWD was associated with both Borg dyspnea (coefficient –17 m per unit increase in Borg dyspnea [95%CI –27, –8]) and end-exercise SpO₂ (coefficient 8 m [95%CI 4, 12]) (both p<0.001). A sensitivity analysis using the delta SpO₂ (i.e., end-exercise SpO₂ – baseline SpO₂) demonstrated similar results (coefficient 7 m per unit increase in delta SpO₂ [95%CI 2, 13; p=0.004]). Borg fatigue was not associated with 6MWD. When Borg dyspnea and end-exercise SpO₂ were included as co-primary predictors in a single model, both variables remained independently associated with 6MWD with coefficients of –13 m (95%CI –22, –3) and 7 m (95%CI 3, 10), respectively, after adjusting for covariates (Table 2).

A lower 6MWD was independently associated with exertional dyspnea and hypoxemia, suggesting that dyspnea and hypoxemia may have distinct mechanisms through which they impact functional capacity. Of the patients who had exertional hypoxemia (i.e., SpO₂ decline ≥4%), 45% had a walk distance less than the lower limits of normal (LLN) and 100% had a DL_{CO}<LLN, which suggests that desaturation during exercise is associated with parenchymal and/or pulmonary vascular phenomena. Although dyspnea is typically accompanied by hypoxemia during acute COVID-19 illness,⁶ our study found that exertional dyspnea predicted reduced functional capacity, regardless of whether end-exercise hypoxemia was present or not. The underlying mechanisms of persistent dyspnea after COVID-19 remain

<https://doi.org/10.1016/j.pulmoe.2021.03.004>

2531-0437/© 2021 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Table 1 Patient characteristics. Patients with mild (no hypoxemia), moderate (hypoxemia without mechanical ventilation), and severe (hypoxemia with mechanical ventilation) are shown. An obstructive pattern was defined as FEV₁/FVC < LLN. A restrictive pattern was defined as normal FEV₁/FVC with FVC-% predicted < LLN. Lung volumes using body plethysmography were unavailable.

	Overall (n = 225)	Mild (n = 63)	Moderate (n = 144)	Severe (n = 18)
Age, years	47 ± 13	42 ± 11	49 ± 14	51 ± 8
Male sex, n (%)	139 (62)	31 (49)	92 (64)	16 (89)
BMI, kg/m ²	32 ± 7	30 ± 7	33 ± 7	33 ± 10
Current or former smoker, n (%)	43 (19)	17 (27)	24 (17)	9 (50)
Comorbidities, n (%)				
Obesity	115 (51)	24 (38)	82 (57)	9 (50)
Hypertension	47 (21)	8 (13)	32 (22)	7 (39)
Diabetes	32 (14)	3 (5)	27 (19)	2 (11)
Other ^a	15 (7)	3 (5)	11 (8)	1 (6)
Symptoms at follow-up, n (%)				
Fatigue on effort	153 (68)	37 (59)	102 (71)	14 (78)
Dyspnea	87 (39)	20 (32)	58 (40)	9 (50)
Chest pain	68 (30)	12 (19)	53 (37)	3 (17)
Myalgias	70 (31)	18 (29)	46 (32)	6 (33)
Cough	69 (31)	18 (29)	43 (30)	8 (44)
Sore throat	40 (18)	8 (13)	27 (19)	5 (28)
Sputum production	38 (17)	7 (11)	26 (18)	5 (28)
Headache	32 (14)	12 (19)	19 (13)	1 (6)
Rhinitis	32 (14)	10 (16)	22 (15)	0 (0)
Anosmia/ageusia	23 (10)	6 (10)	16 (11)	1 (6)
Dermatological symptoms	23 (10)	6 (10)	17 (12)	0 (0)
Diarrhea	6 (3)	2 (3)	4 (3)	0 (0)
Pulmonary function				
FVC, %-predicted	82 ± 19	95 ± 13	79 ± 18	61 ± 19
FEV ₁ , %-predicted	87 ± 19	97 ± 13	85 ± 19	68 ± 21
FEV ₁ /FVC, %	85 ± 7.4	83 ± 5	86 ± 8	88 ± 4
D _{LCO} , %-predicted	97 ± 29	112 ± 20	93 ± 27	65 ± 34
Restrictive pattern, n (%)	87 (39)	7 (11)	66 (46)	14 (78)
Obstructive pattern, n (%)	5 (2)	2 (3)	3 (2)	0 (0)
6-min walk test				
Distance, m	447 ± 104	491 ± 72	433 ± 111	425 ± 94
Distance, %-predicted	83 ± 20	83 ± 14	83 ± 21	86 ± 21
Baseline SpO ₂ , %	96 ± 2	97 ± 1	96 ± 2	96 ± 1
End-exercise SpO ₂ , %	95 ± 4	97 ± 2	95 ± 2	93 ± 5
Peak dyspnea, Borg 0–10	2 (1–3)	2 (1–3)	2 (1–3)	3 (2–4)
Peak fatigue, Borg 0–10	2 (0–3)	2 (1–4)	2 (0–3)	0 (0–2)

Abbreviations: BMI, body mass index; FEV₁, forced expiratory volume in one second; FVC, forced vital capacity; SpO₂, oxygen saturation by pulse oximetry.

^a Other comorbidities include asthma, malignancy, dyslipidemia, and HIV. Values represent mean ± standard deviation or median (interquartile range), unless otherwise specified.

unclear; however, it is likely that physiologic sequelae contribute to this lingering symptom. In a previous study using the same cohort, we demonstrated that patients with persistent dyspnea had lower FVC, forced expiratory volume in 1 s, and higher proportion of restrictive ventilatory pattern compared to patients without persistent dyspnea.⁶ Furthermore, patients with abnormal DL_{CO} at follow-up are more likely to have an elevated D-dimer on admission, suggesting that microangiopathies could contribute to dyspnea.⁷

This study had several limitations. First, our data did not include validated tools such as the Charlson Comorbidity Index to assess how comorbidities impact

6MWD. Second, this study was from a single Mexican center. However, this unique population adds to the understanding of COVID-19 recovery in diverse patient backgrounds. Third, we did not have information on treatment during the acute illness which could impact outcomes.

We demonstrate the impact that persistent dyspnea and hypoxemia have on functional capacity in patients after COVID-19. Further research to understand the underlying mechanisms of persistent symptoms, particularly dyspnea that is disproportionate to physiologic and radiologic findings, is needed in order to help patients recovering from COVID-19.

Table 2 Mechanisms of reduced 6-min walk distance after COVID-19 illness.

Model	Outcome	Unadjusted analysis			Adjusted analysis			Prespecified covariates	
		Primary predictor(s)	Coefficient	95%CI	P-value	Coefficient	95%CI		P-value
1a	6MWD	BORG dyspnea	−22	−33, −12	<0.001	−17	−27, −8	<0.001	Age, sex, smoker, BMI, time ^a
1b	6MWD	BORG fatigue	−5	−13, 4	0.277	−4	−11, 4	0.298	Age, sex, smoker, BMI, time
1c	6MWD	End-exercise SpO ₂	8	4, 11	<0.001	8	4, 12	<0.001	Age, sex, smoker, BMI, time
2	6MWD	BORG dyspnea	−18	−29, −7	<0.001	−13	−22, −3	0.009	Age, sex, smoker, BMI, time
		End-exercise SpO ₂	6	2, 10	0.004	7	3, 10	<0.001	

Abbreviations: 6MWD, 6-min walk distance; BMI, body mass index; CI, confidence interval, SpO₂, oxygen saturation by pulse oximetry.

^a Time from symptom onset.

Funding

The authors received no funding for this work.

Conflict of interest

The authors have no conflicts of interest to declare.

References

- Shah AS, Wong AW, Hague CJ, Murphy DT, Johnston JC, Ryerson CJ, et al. A prospective study of 12-week respiratory outcomes in COVID-19-related hospitalisations. *Thorax*. 2021;76:402–4, <http://dx.doi.org/10.1136/thoraxjnl-2020-216308>.
- Wong AW, Shah AS, Johnston JC, Carlsten C, Ryerson CJ. Patient-reported outcome measures after COVID-19: a prospective cohort study. *Eur Respir J*. 2020;56(5), <http://dx.doi.org/10.1183/13993003.03276-2020>.
- Graham BL, Brusasco V, Burgos F, Cooper BG, Jensen R, Kendrick A, et al. 2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung. *Eur Respir J*. 2017;49(1), <http://dx.doi.org/10.1183/13993003.00016-2016>.
- Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL, et al. Standardization of spirometry 2019 update. An Official American Thoracic Society and European Respiratory Society Technical Statement. *Am J Respir Crit Care Med*. 2019;200(8):e70–88, <http://dx.doi.org/10.1164/rccm.201908-1590ST>.
- ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. *Am J Respir Crit Care Med*. 2002;166(1):111–7, <http://dx.doi.org/10.1164/ajrccm.166.1.at1102>.
- Cortés-Telles A, López-Romero S, Figueroa-Hurtado E, Pou-Aguilar YN, Wong AW, Milne KM, et al. Pulmonary function and functional capacity in COVID-19 survivors with persistent dyspnea. *Respir Physiol Neurobiol*. 2021;288:103644, <http://dx.doi.org/10.1016/j.resp.2021.103644>. Epub 2021 Feb 27.
- Zhao YM, Shang YM, Song WB, Li QQ, Xie H, Xu QF, et al. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. *EclinicalMedicine*. 2020;25:100463, <http://dx.doi.org/10.1016/j.eclinm.2020.100463>.

A.W. Wong^{a,b}, S. López-Romero^c, E. Figueroa-Hurtado^d, S. Vazquez-Lopez^d, K.M. Milne^{a,b}, C.J. Ryerson^{a,b}, J.A. Guenette^{b,e,1}, A. Cortés-Telles^{d,*1}

^a Department of Medicine, The University of British Columbia, Vancouver, Canada

^b Centre for Heart Lung Innovation, Providence Health Care Research Institute, The University of British Columbia and St. Paul's Hospital, Vancouver, Canada

^c Internal Medicine Department, Hospital Regional de Alta Especialidad de la Península de Yucatán, Yucatán, Mexico

^d Respiratory and Thoracic Surgery Unit, Hospital Regional de Alta Especialidad de la Península de Yucatán, Yucatán, Mexico

^e Department of Physical Therapy, The University of British Columbia, Vancouver, Canada

* Corresponding author at: Respiratory and Thoracic Unit, Hospital Regional de Alta Especialidad de la Península de Yucatán, Calle 7 # 433 por Calle 20 y Calle 22, Col. Altabrisa, 97133 Mérida, Yucatán, Mexico.

E-mail address: dr.morenheim@hotmail.com

(A. Cortés-Telles).

¹ Co-senior authors.

11 January 2021

Available online 26 March 2021